Oric Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, dedicated to developing oral targeted therapies designed to overcome fundamental cancer resistance mechanisms. The company’s research strategy centers on identifying and inhibiting key signaling pathways and microenvironmental factors that drive tumor survival and proliferation. By focusing on oral small molecules, Oric aims to provide patients with convenient, potentially more tolerable treatment options compared with intravenous regimens.
The company’s lead programs include ORIC-101, a selective oral glucocorticoid receptor antagonist in Phase 1/2 clinical studies for solid tumors, and ORIC-944, a potent inhibitor of the cell-cycle checkpoint kinase Wee1 currently under evaluation in advanced cancer indications. In addition to its clinical-stage assets, Oric maintains a preclinical pipeline targeting mechanisms such as fibroblast growth factor receptor (FGFR) aberrations and other cell-cycle dependencies. Oric’s early-stage studies are being conducted across multiple sites in the United States and Europe, often in collaboration with leading academic cancer centers.
Founded in 2016 by a team led by Dr. Roger M. Perlmutter—a veteran pharmaceutical executive and former president of Merck Research Laboratories—and Dr. Jay Bradner of Harvard’s Novartis Institute for Biomedical Research, Oric has built a leadership team with deep expertise in oncology drug development. The company is led by President and Chief Executive Officer Todd Braunstein, who brings extensive experience in global biopharmaceutical strategy and operations. Its board and scientific advisory group include seasoned leaders from both industry and academia.
Oric Pharmaceuticals serves patients and healthcare providers worldwide, with a mission to deliver next-generation therapies that address the adaptive resistance often seen with current cancer treatments. By combining insights from cancer biology with a focus on oral delivery, Oric seeks to advance a portfolio of best-in-class candidates that can meaningfully improve outcomes for patients facing challenging solid tumor diagnoses.
AI Generated. May Contain Errors.
